Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High – Time to Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s stock price hit a new 52-week high on Friday . The company traded as high as $21.93 and last traded at $21.91, with a volume of 170293 shares traded. The stock had previously closed at $21.41.

Wall Street Analyst Weigh In

CPRX has been the topic of several research reports. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright raised their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Citigroup lifted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Stock Performance

The stock has a market capitalization of $2.57 billion, a PE ratio of 39.65, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. The business’s 50-day moving average price is $20.34 and its 200 day moving average price is $17.56.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. As a group, equities research analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares of the company’s stock, valued at $227,836.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 201,058 shares of company stock valued at $4,018,188 over the last three months. 11.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the last quarter. nVerses Capital LLC purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at about $50,000. CWM LLC grew its position in Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Catalyst Pharmaceuticals during the 2nd quarter worth approximately $70,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Catalyst Pharmaceuticals in the 2nd quarter worth approximately $153,000. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.